Do Oral and Injectable Methotrexate Dosages Differ?
Yes, methotrexate dosages often differ between oral and injectable forms due to differences in bioavailability. Oral methotrexate has lower and more variable absorption (about 60-90% in low doses, dropping at higher doses), while subcutaneous or intramuscular injections achieve nearly 100% bioavailability, allowing equivalent effects at lower doses.[1][2]
What Are Typical Dosages for Each Form?
For rheumatoid arthritis (RA), the most common indication:
- Oral: Starts at 7.5 mg once weekly, titrated up to 20-25 mg weekly, split into 2-3 doses taken 12 hours apart to improve absorption.[1][3]
- Subcutaneous (preferred injectable): Equivalent weekly dose is often 10-25 mg, but many patients use 15 mg weekly—about 20-30% lower than oral for the same efficacy due to better absorption.[2][4]
In psoriasis or cancer (e.g., leukemia), injectables are used for higher doses (up to 25-50 mg/m² IV/IM weekly or more), where oral isn't feasible.[1]
| Indication | Oral (weekly) | Subcutaneous/IM (weekly) |
|------------|---------------|--------------------------|
| RA | 7.5-25 mg | 7.5-25 mg (often lower end) |
| Psoriasis | 10-25 mg | 10-30 mg |
Doses are individualized based on weight, response, and toxicity monitoring.[3]
Why Do Doctors Switch from Oral to Injectable?
Switching occurs when oral absorption fails (e.g., in elderly patients or at doses >15 mg/week), causing inadequate response or GI side effects. Injectables reduce nausea and improve consistency, with studies showing 30% better efficacy at equivalent nominal doses.[2][4] Guidelines from the American College of Rheumatology recommend subcutaneous for non-responders to oral.[3]
Are Side Effects or Monitoring Different?
No major differences in side effects (nausea, fatigue, liver toxicity, bone marrow suppression), but injectables cause less GI upset. All forms require baseline blood tests (liver enzymes, CBC) and monitoring every 4-8 weeks, with folate supplementation to mitigate risks.[1][3]
Cost and Availability Factors
Injectables (prefilled syringes like Otrexup or Rasuvo) cost more ($300-600/month) than generic oral tablets ($10-50/month), but insurance often covers switches for poor oral response. Biosimilars aren't applicable as methotrexate is off-patent.[5]
Sources
[1] FDA Label: Methotrexate
[2] PubMed: Bioavailability comparison
[3] ACR RA Guidelines 2021
[4] Annals of Rheumatic Diseases study
[5] Drugs.com Pricing